Imatinib Mesylate is an inhibitor of tyrosine kinase activity of chimeric BCR-ABL gene, situated at chromosome 22, and has been considered as a “targeted therapy” in the management of chronic myeloid leukemia . Complete hematologic response was achieved in chronic and accelerated phases in 39 (90.6%) patients within 1 – 2 months of the therapy with Imatinib Mesylate. In patients with complete hematologic response the repeated cytogenetic examination of the bone marrow revealed the decrease of myeloid cells bearing Phchromosome up to 0 – 35%, that certified the major or complete cytogenetic remission.

Imatinib Mesilat este inhibitor al activitatii tirozinkinazice a genei himerica BCR-ABL situate pe cromozomul 22 si se considera ca „terapia în tinta ” în managementul leucemiei mieloide cronice. Ra spunsul clinico-hematologic complet a fost obtinut în faza cronica s i accelerata la 39 (90,6%) pacient i peste 1 – 2 luni de terapie cu Imatinib Mesilat. La bolnavii cu remisiunea clinico-hematologica completa analiza citogenetica repetata a maduvei osoase a demonstrat scaderearatei celulelor medulare pozitive la Ph-cromozom pîna la 0 – 35%, ce indica obt inerea remisiunii citogenetice majore sau complete.